 PRINCETON, N.J., April 26, 2021 PRNewswire -- Soligenix, Inc. Nasdaq: SNGX Soligenix or the Company, a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Ellen Kim, MD, Medical Director, Dermatology Clinic, Perelman Center for Advanced Medicine, Professor of Dermatology at the Hospital of the University of Pennsylvania, and the Lead Principal Investigator for the Phase 3 FLASH Fluorescent Light Activated Synthetic Hypericin study, delivered a presentation at the American Academy of Dermatology AAD Association Virtual Meeting Experience, held April 23-25, 2021. 